Last reviewed · How we verify
Gene-modified autologous fibroblasts
Gene-modified autologous fibroblasts is a Small molecule drug developed by King's College London. It is currently in Phase 1 development. Also known as: COL7A1 gene-modified autologous fibroblasts.
At a glance
| Generic name | Gene-modified autologous fibroblasts |
|---|---|
| Also known as | COL7A1 gene-modified autologous fibroblasts |
| Sponsor | King's College London |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (PHASE3)
- Evaluation of D-Fi for the Treatment of Wounds Due to DEB (PHASE3)
- Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine (PHASE1)
- Safety Study of Gene-modified Autologous Fibroblasts in Recessive Dystrophic Epidermolysis Bullosa (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gene-modified autologous fibroblasts CI brief — competitive landscape report
- Gene-modified autologous fibroblasts updates RSS · CI watch RSS
- King's College London portfolio CI
Frequently asked questions about Gene-modified autologous fibroblasts
What is Gene-modified autologous fibroblasts?
Gene-modified autologous fibroblasts is a Small molecule drug developed by King's College London.
Who makes Gene-modified autologous fibroblasts?
Gene-modified autologous fibroblasts is developed by King's College London (see full King's College London pipeline at /company/king-s-college-london).
Is Gene-modified autologous fibroblasts also known as anything else?
Gene-modified autologous fibroblasts is also known as COL7A1 gene-modified autologous fibroblasts.
What development phase is Gene-modified autologous fibroblasts in?
Gene-modified autologous fibroblasts is in Phase 1.
Related
- Manufacturer: King's College London — full pipeline
- Also known as: COL7A1 gene-modified autologous fibroblasts
- Compare: Gene-modified autologous fibroblasts vs similar drugs
- Pricing: Gene-modified autologous fibroblasts cost, discount & access